Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Saltarelli is in the catbird seat...
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(113)
•••
Comment by prophetoffactzon Jan 10, 2023 9:31am
122 Views
Post# 35213077

RE:RE:RE:Saltarelli is in the catbird seat...

RE:RE:RE:Saltarelli is in the catbird seat...",,No matter what way you cut it,,the BTI management team failed us miserably in pushing this technology forward,,,,however they have had no problem pushing themselves forward these past years."

Saltarelli has a choice with his time in this business given his serial success in biotech. I think BTI's misfortune held him back and was very costly to him given he could have went elsewhere and succeeded. He looks like a believer in BTI despite the setbacks. The set-back of COVID and the worst biotech market in history have had a toll on BTI. Timelines in preclinical biotech can also be long, very frusterating,and uncertain. Saltarelli is excited about Biodexa which should be on sound financial footing as BTI never saw, and with re-risked clinical programs that can push forward and help support preclinical programs like Q-Sphera, and xB3. Biodexa is a much stronger foundation than BTI ever was; especially for this difficult time in the market. 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities